



GREEN PLANET MICROCAPS
ESG MICROCAP SPECIALISTS

Our treasure chest is filled with inspiring young companies that have innovative solutions to address a clean, low-carbon environment and to provide disruptive technologies to make life better

TOMORROW'S WINNERS TODAY

SEE WHY THE ADMT 'SONOTRON' COULD REVOLUTIONIZE THE WAY PAIN IS TREATED

THIS REMARKABLE VIDEO SHOWS THE SONOTRON ELIMINATING SEVERE PAIN AND INFLAMMATION IN MINUTES – LONG LASTING TREATMENT USES NO DRUGS AND HAS NOT SHOWN ANY ADVERSE SIDE EFFECT





ADM Tronics (OTCQB-ADMT) Engineering Services medical electronic devices

ADM TRONICS DEMONSTRATES REMARKABLE NON-DRUG PAIN BREAKTHROUGH

- The [Institute for Health Metrics and Evaluation](#) reported that in 2016 Americans spent about \$300 billion to treat pain.
- There have been many pain treatment devices over the years, but not one has ever come close to the Sonotron. Watch this video and be amazed!
- ADM Tronics developed a pain management device that can revolutionize the way pain is treated. The Sonotron treats pain and inflammation in a few minutes - without any drugs or adverse side effects - and demonstrates remarkable and long-lasting results.
- ADMT plans to launch its Sonotron® pain management device for pets and horses within the next year and will then seek FDA clearance for human use
- ADMT has no debt and just under 68 million shares outstanding. With a recent closing price of \$.12, the market cap is a very small \$8,160,000

For over 40 years, ADM Tronics Unlimited, Inc. (ADMT: OTC), has been designing, engineering, and providing regulatory and manufacturing services for precision electronics with a particular expertise in electronic medical devices for therapeutics and diagnostics at its FDA-Registered medical device facility in Northvale, New Jersey USA.

The company has developed several medical devices and will soon be launching its game-changing Sonotron pain management device for pets and horses, followed by a submission to the FDA for approval for human use. This [video demonstration](#) shows how remarkably effective the Sonotron pain treatment is and how quickly it works. The video shows a racehorse that was suffering from noticeable pain and inflammation. After one 18 minute treatment with the Sonotron pain device, the horse was noticeably pain free and the visible inflammation was no longer present.

The Sonotron shows promise of being a game-changing breakthrough to treat pain with no drugs and no side effects. The market for pain treatment for horses and dogs and pets is quite large, but the market for pain treatment for human patients is even larger with Americans spending over \$300 billion in 2016 to treat pain. With results like the ones shown in the video, the Sonotron could become an extremely valuable asset of ADM Tronics and could have a substantial impact on ADMT share prices.

Sonotron has completed evaluation and is now in the commercialization phase

The Sonotron pain treatment device is now operational and in the queue for commercialization. In November of 2021, ADM Tronics announced they had completed the evaluation stage and were entering the commercialization stage. Here is that [press release](#):

ADM Tronics Releases Pre-Production Evaluation Units of New Vet-Sonotron Therapy Device for Veterinary Market

ADM Tronics Unlimited, Inc. has completed development of its new Vet-Sonotron® device and has released pre-production evaluation units for the animal therapy markets.

The Vet-Sonotron is a veterinary electronic therapy device for the treatment of musculoskeletal pain and inflammation associated with degenerative conditions and trauma in small animals - dogs and cats - and large animals, primarily equine such as thoroughbred, standardbred, hunters and jumpers, dressage, etc. The Vet-Sonotron employs pulsed radio frequency therapy ("PRFT") to produce a discharge output. The PRFT output is emitted through a hand-held applicator that is applied non-invasively in a circular motion over the treatment area. Vet-Sonotron produces a microprocessor-controlled 15-second output of the PRFT discharge - termed a "Treatment Unit" or "TU". The number of TUs administered depends on the size and density of the treatment area with a typical treatment session lasting

only minutes. Depending on the severity of the condition treated, several treatment sessions are administered to achieve optimum results. “This is an important milestone for our company,” stated Andre’ DiMino, President of ADM Tronics. “Once this evaluation stage for the Vet-Sonotron is completed, we are anxious to begin commercialization of the Vet-Sonotron to the animal therapy markets. We believe our PRFT technology can have a meaningful impact in treating many debilitating conditions in animals.” In controlled studies the Vet-Sonotron PRFT therapy has resulted in reduced lameness, increased range of motion and other improvements in conditions and diseases in animals.

The Vet-Sonotron is one of a number of proprietary electronic therapy devices under development by ADMT. In addition to development of its own proprietary technologies, ADMT provides design, engineering, regulatory and contract manufacturing services for medical and veterinary technologies to customers at its FDA-registered medical device manufacturing facility in Northvale, NJ.

<https://admtronics.com/medical/proprietary-products/>

The Sonotron is a non-invasive electrotherapy technology used to treat pain. It uses a novel combination of long-wave RF energy pulsed at an audio frequency to produce a corona discharge output. The first version of the Sonotron has been manufactured and distributed by ADMT in certain countries in Southeast Asia. ADMT is in the process of re-engineering the Sonotron with state-of-the-art digital, wireless connectivity to allow for higher patient compliance, ease of professional use and cloud adaptability. Once the new version of the Sonotron has been completed application to the FDA will be submitted for clearance to market in the US. The Sonotron has significant potential for use in the treatment of joint pain, such as osteoarthritis, tendinitis, bursitis, TMJ and other painful conditions representing a multi-billion dollar market.

The Sonotron technology is our own technology. We are in the process of finalizing the Vet-Sonotron, which is the veterinary version of the Sonotron. We will be commercializing the Vet-Sonotron soon and then we will be working on the Sonotron (human medical version) for submission to the FD - but that will be from 9 to 12 months from now.

The Sonotron technology is for the treatment of pain related to musculoskeletal conditions. The Vet-Sonotron is for treating those conditions in animals – such as horses and dogs

Here is a video of a race horse that had dramatic improvement after being treated with the Ve-Sonotron for just a few minutes:

<https://youtu.be/yPjbQ7Ry34s>

Here is a video of a dog that could not walk due to hip dysplasia, that began walking after being treated with the Vet-Sonotron:

https://youtu.be/jd_4mUnktwo

Conclusion

Several factors are aligned to highlight the opportunity that ADM Tronics has created with the Sonotron pain management device. First; the market is very large with Americans spending over \$300 billion in 2016 to treat pain; second, no known device has been able to compete with drugs such as opioids that are a double-edged sword because they can cause more problems than they solve; and third, the Sonotron continues to demonstrate unmatched pain and inflammation relief compared to any non-drug treatments.

ADM Tronics is an established leader in electronic medical devices and also generates substantial income from fees for engineering products for other companies and for taking other third-party products through the challenging FDA approval process. With only 68 million shares outstanding and no debt, ADM Tronics appears to be positioned to enjoy solid growth in the near and long term. In over 40 years of operating history, ADM Tronics has managed to mitigate risks and make money. Factoring in the Sonotron, suggests potential growth that could be far above investor expectations.

Legal Disclosures and Disclaimers

Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.

Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.

Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.

Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.

Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands" or that by statements indicating certain actions "may", "could", or "might" occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from. Green Planet Microcaps was compensated \$3,300 for this article and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap's website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber's inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.

Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber's behalf under any circumstances.